Cited 100 time in
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Choi, Chang-Ik | - |
| dc.date.accessioned | 2024-09-26T12:01:57Z | - |
| dc.date.available | 2024-09-26T12:01:57Z | - |
| dc.date.issued | 2016-09 | - |
| dc.identifier.issn | 1420-3049 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/24969 | - |
| dc.description.abstract | Diabetes mellitus is a chronic condition associated with the metabolic impairment of insulin actions, leading to the development of life-threatening complications. Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, weight gain, and hepato-renal toxicity, have increased demand for the discovery of novel, safer antidiabetic drugs. Since the important roles of the sodium-glucose cotransporter 2 (SGLT2) for glucose homeostasis in the kidney were recently elucidated, pharmacological inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes. Since the discovery of the first natural SGLT2 inhibitor, phlorizin, several synthetic glucoside analogs have been developed and introduced into the market. Furthermore, many efforts to find new active constituents with SGLT2 inhibition from natural products are still ongoing. This review introduces the history of research on the development of early-generation SGLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI AG | - |
| dc.title | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/molecules21091136 | - |
| dc.identifier.scopusid | 2-s2.0-84987877197 | - |
| dc.identifier.wosid | 000385479800033 | - |
| dc.identifier.bibliographicCitation | MOLECULES, v.21, no.9 | - |
| dc.citation.title | MOLECULES | - |
| dc.citation.volume | 21 | - |
| dc.citation.number | 9 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
| dc.subject.keywordPlus | TYPE-2 DIABETES-MELLITUS | - |
| dc.subject.keywordPlus | INADEQUATE GLYCEMIC CONTROL | - |
| dc.subject.keywordPlus | DAILY REMOGLIFLOZIN ETABONATE | - |
| dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
| dc.subject.keywordPlus | PROXIMAL TUBULAR CELLS | - |
| dc.subject.keywordPlus | DOUBLE-BLIND | - |
| dc.subject.keywordPlus | SERGLIFLOZIN ETABONATE | - |
| dc.subject.keywordPlus | SELECTIVE INHIBITOR | - |
| dc.subject.keywordPlus | NA+/GLUCOSE COTRANSPORTER | - |
| dc.subject.keywordPlus | DOSE PHARMACOKINETICS | - |
| dc.subject.keywordAuthor | type 2 diabetes mellitus | - |
| dc.subject.keywordAuthor | sodium-glucose cotransporter | - |
| dc.subject.keywordAuthor | SGLT2 inhibitor | - |
| dc.subject.keywordAuthor | natural product | - |
| dc.subject.keywordAuthor | phlorizin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
